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Abstract A 17-year-old patient with sickle cell-beta
thalassemia undergoing treatment with home iron chela-
tion therapy inadvertently received ten times the recom-
mended dose of intravenous deferoxamine. Acute renal
failure (ARF) developed within hours. Immediate treat-
ment with high-efficiency hemodialysis resulted in the
prompt return of renal function after only one hemodial-
ysis session. No long-term nephrotoxic effects of the
deferoxamine overdose developed after more than 1 year
of follow-up. Children with sickle cell disease who are
on intravenous deferoxamine and their parents should be
cautioned about the possibility of ARF with overdose
due to malfunction of the pump and/or inadequate moni-
toring during treatment. ARF, should it occur in such
children, appears to respond well to treatment with high-
efficiency hemodialysis.
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Introduction
Iron chelation therapy with deferoxamine has become
the mainstay of treatment of patients with thalassemia
and other transfusion-dependent anemias. It has effec-
tively prolonged survival and reduced morbidity from
iron overload caused by the frequent transfusions re-
quired by these patients [1]. Deferoxamine therapy, how-
ever, is not without risks and complications. In this case,
a teenage boy with sickle cell-beta thalassemia devel-
oped acute renal failure (ARF) following an accidental
deferoxamine overdose. Prompt institution of hemodial-
ysis led to a complete recovery of renal function.
Case report
The patient was a 17-year-old African-American boy with sickle
cell-beta thalassemia who became severely iron overloaded as a
consequence of chronic blood transfusions and noncompliance
with either nightly subcutaneous or intravenous iron chelation
with desferrioxamine (Deferoxamine, Desferal, Novartis Pharma-
ceuticals, East Hanover, N.J., USA). Among his many sickle cell-
related complications, he had a prior history of hematuria and pap-
illary necrosis of the kidneys at age 15 years and again at 16 years.
Because of concern over the degree of iron overload, the pa-
tient and his mother were offered a more convenient schedule of
deferoxamine, 700 mg/kg per week administered as a continuous
96-h infusion. A home intravenous AIM pump (Abbott Medical
Products, San Diego, Calif., USA) and instructions regarding its
programming were provided. Over the next 9 months his serum
ferritin slowly dropped from 8,000 to 2,000 µg/l.
On one occasion his mother accidentally programmed his
pump to deliver the full 96-h dose of 45 g (700 mg/kg) over a pe-
riod of 8 h. He presented the next day to the emergency room with
a complaint of generalized itching, a burning sensation of the skin,
shortness of breath, chest pain, crampy abdominal pain, and de-
creased urine output.
Physical examination revealed blood pressure of 147/82 mmHg,
heart rate of 108 beats/min, temperature of 36.5°C, and pulse 
oximetry of 100% in room air. There were no signs of dehydration
or fluid overload and the remainder of his examination was unre-
markable. Laboratory data demonstrated significant metabolic aci-
dosis and azotemia (Table 1). The urine was red-orange in color as
is characteristic during iron chelation. Urinalysis revealed pH 5.0,
specific gravity 1.020, protein 15 mg/dl, and trace blood. Micro-
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scopic examination revealed 25–50 hyaline casts per high-power
field (hpf), 3–5 white blood cell casts/hpf, and no red blood cells.
Liver enzymes were elevated (Table 1), but these results were not
appreciably different from baseline measurements obtained over
the preceding 6 months. Serum iron was 122 mg/dl and serum 
ferritin was 2,009 µg/l. Chest radiograph was normal.
Despite intravenous hydration and forced diuresis with manni-
tol, the patient remained oliguric, with urine output of just 200 ml
over the next 8 h (0.5 ml/kg per hour) and onset of hypertension
(blood pressure 140/93 mmHg). Because of the rapid onset of
oliguria, the development of hypertension, progressive azotemia
(Table 1), and the lack of response to more conservative measures,
hemodialysis was recommended. A 12-Fr triple-lumen femoral he-
modialysis catheter was placed, and high-efficiency hemodialysis
performed utilizing a cellulose triacetate hollow-fiber dialyzer
(CT-190, Baxter Healthcare, Deerfield, Ill., USA), standard dialy-
sate flow rate, and blood flow rate of 400 ml/min (8.2 ml/kg per
min). Dialysis (3 h) was performed without incident. The patient
remained stable throughout. Serum was drawn prior to and follow-
ing dialysis for possible determination of deferoxamine levels, but
no laboratory able to perform this test could be identified, despite
contacting the manufacturer. A gradual change in the color of the
patient’s urine from cloudy orange to clear amber was observed
following completion of hemodialysis.
Following dialysis, the patient’s urine output increased tenfold
to 2,050 ml/8 h (5.2 ml/kg per hour), and his creatinine continued
to fall (Table 1). Recovery of renal function was accompanied by
the development of mild hypertension that was treated with oral
isradipine for 12 days. At 1 month post hospitalization the patient
was well, with normal blood pressure, normal urine output, a cre-
atinine of 0.6 mg/dl, and no obvious residual renal sequelae. At
last follow-up, 1 year after the episode of renal failure, his creati-
nine was 0.7 mg/dl, electrolytes were within normal limits, and he
remained normotensive.
Discussion
Mortality and morbidity in thalassemia and similar he-
matological conditions are caused in part by iron over-
load leading to myocardial siderosis, hepatic fibrosis,
and endocrine complications such as diabetes and hypo-
thyroidism. Deferoxamine removes chelatable iron from
parenchymal tissues and the reticuloendothelial system
[2], and has been used successfully in iron overload
states [1]. It is the only widely available treatment for
prophylaxis against iron accumulation in vital organs,
such as the liver, heart, and the endocrine system, in pa-
tients undergoing chronic blood transfusion therapy [3].
Recently, continuous infusions of deferoxamine, as per-
formed in our patient, have been shown to be an effec-
tive alternative approach for patients with life-threaten-
ing iron overload and/or unable to tolerate subcutaneous
infusions of deferoxamine [4].
Numerous side effects of deferoxamine chelation
have been reported, including abnormal skeletal growth
[5], retinal toxicity [6], ototoxicity [7], sensorimotor tox-
icity [8], pulmonary embolism [9], and nephrotoxicity
[10, 11, 12]. Most of these toxicities can be avoided with
close monitoring during deferoxamine therapy, decreas-
ing the doses appropriately or discontinuing the drug at
the appearance of signs of toxicity [7, 8].
Deferoxamine has been demonstrated to affect renal
hemodynamics in animal studies, decreasing renal blood
flow and glomerular filtration rate. Koren et al. [10] re-
ported three patients who developed temporary, acute de-
creases in creatinine clearance after receiving high-dose
deferoxamine that returned to baseline when the infu-
sions were discontinued. The fact that deferoxamine 
inhibits vascular prostacyclin synthesis in vitro [13] sug-
gests that it may also play a role in preventing the nor-
mal activation of the renin angiotensin system that usual-
ly occurs in hypovolemic states, thereby setting the stage
for the development of azotemia. Finally, a proximal tu-
bular defect may occur that can inhibit the reabsorption
of sodium, potassium, and phosphates, resulting in a rel-
ative diuresis, and contributing further to development of
a hypovolemic state. Moreover, although deferoxamine-
associated nephrotoxicity is largely dose dependent, if a
patient has underlying renal dysfunction, ARF can occur
even with usual therapeutic doses [12].
There have been two previous reports of ARF in chil-
dren treated with intravenous deferoxamine [12, 14]. In
the first report, a teenager with thalassemia major with
hepatic and cardiac failure due to iron overload devel-
oped ARF after 9 days of high-dose intravenous defer-
oxamine and subsequently died while receiving perito-
neal dialysis. In the second case, ARF developed after a
teenager accidentally received 700 mg/kg of deferoxam-
ine over 18 h. Onset of ARF was rapid, and hemodialy-
sis was initiated. The patient underwent 3 days of dialy-
sis utilizing a polyacrylonitrite dialyzer, with restoration
of normal urine output and return of normal renal func-
tion. Clearance of the deferoxamine by dialysis was in-
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Table 1 Laboratory values in
our patient before and after def-
eroxamine overdose (AST aspar-
tate aminotransferase, 
ALT alanine aminotransferase)
Baselinea Pre Post Follow- Long-term 
dialysis dialysis upb follow-upc
Bicarbonate (mEq/l) 28 11 24 24 28
Urea nitrogen (mg/dl) 13 23 6 5 5
Creatinine (mg/dl) 0.4 2.2 0.6 0.6 0.7
Calcium (mg/dl) 9.6 8.5 9.0 9.2 9.1
Potassium (mEq/l) 4.0 4.3 3.8 4.3 3.9
Phosphorus (mg/dl) 4.6 6.6 5.5 3.5 –
AST (IU/l) 55 114 – 53 85
ALT (IU/l) 47 79 – 43 49
Ferritin (µg/l) 1596 2,009 – – –
Hemoglobin (g/dl) 9.4 8.1 7.8 9.0 6.4
Platelet (×103/mm3) 142 – 127 178 360
a Baseline readings were most
recent laboratory values prior
to overdose
b Follow-up readings were 
laboratory values obtained at
first post-dialysis outpatient
clinic visit
c Follow-up readings at 1 year
post acute renal failure
ferred by a fall in urinary iron excretion following dialy-
sis. The long-term renal function of this patient was not
reported.
Our patient received a similar dose of deferoxamine
on milligram per kilogram basis as the second case men-
tioned above. The natural history of ARF following def-
eroxamine overdose is unknown. Early institution of
high-efficiency hemodialysis may have prevented the de-
velopment of severe renal insufficiency and/or long-term
renal sequelae. We were unable to prove clearance of
deferoxamine by dialysis due to the lack of a test for
measurement of deferoxamine levels, but we are reason-
ably sure that dialysis was effective in clearing deferox-
amine from our patient for two reasons. First, deferox-
amine [molecular weight 656.79 kilodalton (package 
insert)] is small enough to be readily removed by the
highly permeable cellulose triacetate dialyzer that was
used. Second, it is thought that ferrioxamine, the iron-
deferoxamine complex, is distributed almost entirely in
the extracellular space, which should make it easily re-
movable by hemodialysis. These pharmacokinetic as-
sumptions are supported by the disappearance of the
characteristic orange color produced by chelated iron
from the patient’s urine after hemodialysis.
Given the effectiveness of continuous outpatient infu-
sions of deferoxamine, especially for otherwise noncom-
pliant patients or those with life-threatening complica-
tions from iron overload, overdoses such as that seen in
our patient may become more common. Home infusion
therapy regimens and newer pumps have made deferox-
amine infusion therapy simpler and more convenient for
patients, but it is important that supervision of the dos-
age and the instructions for pump failure be addressed
adequately with the family. When overdose occurs de-
spite these measures, early institution of hemodialysis
can result in prompt return of renal function without
long-term nephrotoxic effects.
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